A physiologic and pharmacological basis for implementation of incretin hormones in the treatment of type 2 diabetes mellitus

Mayo Clinic Proceedings

Volumn 85, Issue 12 SUPPL., 2010, Pages S5-

  Freeman, Jeffrey S ^a  

^a PHILADELPHIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; ORAL ANTIDIABETIC AGENT; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; UNCLASSIFIED DRUG;

CARDIOVASCULAR RISK; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DIZZINESS; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INFECTION; INJECTION SITE REACTION; INSULIN RELEASE; INSULIN RESISTANCE; LIVER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PANCREATITIS; PATHOGENESIS; PATHOPHYSIOLOGY; PHARMACOLOGY; POSTPRANDIAL STATE; REVIEW; RHINOPHARYNGITIS; SKELETAL MUSCLE; THYROID CANCER; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

EID: 78650154944     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/mcp.2010.0467     Document Type: Article

References (62)

1. DeFronzo RA. Banting Lecture: from the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes. 2009;58(4):773-795.
2. Tabak AG, Jokela M, Akbaraly TN, Brunner EJ, Kivimaki M, Witte DR. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before the diagnosis of type 2 diabetes: an analysis from the Whitehall II study. Lancet. 2009;373(9682):2215-2221.
3. United Kingdom Prospective Diabetes Study Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-853.
4. UK Prospective Diabetes Study Group. UK Prospective Diabetes Study 16: overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44(11):1249-1258.
5. Turner RC, Cull CA, Frighi V, Holman RR; UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA. 1999;281(21):2005-2012.
6. Festa A, Williams K, D'Agostino R Jr, Wagenknecht LE, Haffner SM. The natural course of β-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study. Diabetes. 2006;55(4):1114-1120.
7. Kahn SE. The relative contributions of insulin resistance and betacell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia. 2003;46(1):3-19.
8. Bruce DG, Chisholm DJ, Storlien LH, Kraegen EW. Physiological importance of deficiency in early prandial insulin secretion in non-insulin-dependent diabetes. Diabetes. 1988;37(6):736-744.
9. Kahn SE, Carr DB, Faulenback MV, Utzschneider KM. An examination of β-cell function measures and their potential use for estimating β-cell mass. Diabetes Obes Metab. 2008;10(suppl 4):63-76.
10. Freeman JS. The pathophysiologic role of incretins. J Am Osteopath Assoc. 2007;107(suppl 3):S6-S9.
11. Quesada I, Tuduri E, Ripoll C, Nadal A. Physiology of the pancreatic α-cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol. 2008;199(1):5-19.
12. Kendall DM, Cuddihy RM, Bergenstal RM. Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. Am J Med. 2009;122(6)(suppl):S37-S50.
13. American Diabetes Association. Pathogenesis. In: Burant CF, ed. Medical Management of Type 2 Diabetes. 6th ed. Alexandria, VA: American Diabetes Association: 2008;17-25.
14. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
15. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
16. Lingvay I, Legendre JL, Kaloyanova PF, Zhang S, Adams-Huet B, Raskin P. Insulin-based versus triple oral therapy for newly-diagnosed type 2 diabetes: which is better? Diabetes Care. 2009;32:1789-1795.
17. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3(3):153-165.
18. Kolterman OG, Kim DD, Shen L, et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. Am J Health Syst Pharm. 2005;62(2):173-181. (Pubitemid 40674548)
19. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-1705.
20. Stonehouse A, Okerson T, Kendall D, Maggs D. Emerging incretin-based therapies for type 2 diabetes: incretin mimetics and DPP-4 inhibitors. Curr Diabetes Rev. 2008;4(2):101-109.
21. Baggio LL, Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157.
22. Ban K, Noyan-Asraf H, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and independent pathways. Circulation. 2008;117(18):2340-2350.
23. Elrick H, Stimmler L, Hlad CJ Jr, Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076-1082.
24. Nauck M, Stöckmann F, Ebert R, Creutzfeld W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia. 1986;29(1):46-52. (Pubitemid 16162741)
25. Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab. 2001;86(8):3717-3723. (Pubitemid 32755966)
26. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest. 1993;91(1):301-307.
27. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2005;90(11):5991-5997. (Pubitemid 41606516)
28. Vilsbøll T, Brock B, Perrild H, et al. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic β-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus. Diabet Med. 2008;25(2):152-156.
29. Bunck MC, Diamant M, Corner A, et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care. 2009;32(5):762-768.
30. Klonoff DC, Buse JB, Nielsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin. 2008;24(1):275-286.
31. Cervera A, Wajcberg E, Sriwijitkamol A, et al. Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294(5):E846-E852.
32. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143(11):4397-4408. (Pubitemid 35239574)
33. Farilla L, Bulotta A, Hirshberg B, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology. 2003;144(12):5149-5158.
34. Drucker DJ. Glucagon-like peptide-1 and the islet β-cell: augmentation of cell proliferation and inhibition of apoptosis. Endocrinology. 2003;144(12):5145-5148.
35. Bregenholt S, Moldrup A, Blume N, et al. The long-acting glucagon-like peptide-1 analogue, liraglutide, inhibits β-cell apoptosis in vitro. Biochem Biophys Res Commun. 2005;330(2):577-584. (Pubitemid 40417684)
36. Wang Q, Brubaker PL. Glucagon-like peptide-1 treatment delays the onset of diabetes in 8 week-old db/db mice. Diabetologia. 2002;45(9):1263-1273.
37. DeFronzo RA, Triplitt C, Qu Y, Lewis MS, Maggs D, Glass LC. Effects of exenatide plus rosiglitazone on β cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. Diabetes Care. 2010;33(5):951-957.
38. Madsbad S. Liraglutide Effect and Action in Diabetes (LEAD™) trial. Expert Rev Endocrinol Metab. 2009;4(2):119-129.
39. McGill JB. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med. 2009;121(1):46-58.
40. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab. 2006;91(11):4612-4619.
41. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA. 2007;298(2):194-206.
42. Byetta (exenatide BID) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc; 2009.
43. Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151(4):1473-1486.
44. Crespel A, DeBoisvilliers F, Gros L, Kervran A. Effects of glucagon and glucagon-like-peptide-1 (7-36) amide on C cells from rat thyroid and medullary thyroid carcinoma CA-77 cell line. Endocrinology. 1996;137:3674-3680.
45. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 8th ed. Philadelphia, PA: WB Saunders; 2010.
46. Victoza (liraglutide) [package insert]. Princeton, NJ: Novo Nordisk Inc; 2010. http://www.victozapro.com/pdf/Victoza-ComboPI-5.24.pdf. Accessed October 19, 2010.
47. Noel RA, Braun DK, Patterson RE, et al. Increased risk of acute pancreatitis and biliary disease observed in patients with type 2 diabetes: a retrospective, cohort study. Diabetes Care. 2009;32(5):834-838.
48. Idris I. FDA reviews incidences of acute pancreatitis in patients taking Byetta. Diabetes Obes Metab. 2008;10(1):96-98.
49. Dore DD, Seeger JD, Arnold Chan K. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. Curr Med Res Opin. 2009;25(4):1019-1027.
50. Bloomgren G, Dore D, Patterson R, Noel R, Braun D, Seeger J. Incidence rates for acute pancreatitis in patients with type 2 diabetes initiating exenatide BID compared to initiating other antidiabetic agents: a retrospective cohort study [abstract 158-OR]. Presented at: American Diabetes Association (ADA) 69th Scientific Sessions; June 5-9, 2009; New Orleans, LA. http://professionall.diabetes.org/Abstracts-Display.aspx?TYP=1&CID=74461. Accessed October 19, 2010.
51. Bruce S, MacConell L, Brown C, et al. Safety and tolerability of exenatide BID in patients with type 2 diabetes: integrated analysis of 3854 patients from 11 comparator controlled clinical trials [abstact 578-P]. Presented at: American Diabetes Association (ADA) 69th Scientific Sessions; June 5-9, 2009; New Orleans, LA. http://professional.diabetes.org/Abstracts-Display. aspx?TYP=1&CID=72770. Accessed October 19, 2010.
52. Endocrine and Metabolic Drug Advisory Committee. Liraglutide (injection) for the treatment of patients with type 2 diabetes. NDA 22-341. Briefing document. April 2, 2009. Novo Nordisk, Inc. http://www.fda.gov/ohrms/dockets/ac/ 09/briefing/2009-4422b2-02-NovoNordisk.pdf. Accessed October 28, 2010.
53. Williams-Herman D, Engel SS, Round E, et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
54. Deacon CF. Potential of liraglutide in the treatment of patients with type 2 diabetes. Vasc Health Risk Manag. 2009;5(1):199-211.
55. Nikolaidis LA, Mankad S, Sokos GG, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962-965.
56. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Card Fail. 2006;12(9):694-699. (Pubitemid 44881367)
57. Mannucci E, Ognibene A, Cremasco F, et al. Effect of metformin on glucagon-like peptide-1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care. 2001;24(3):489-494. (Pubitemid 32198418)
58. Cuthbertson J, Patterson S, O'Harte FP, Bell PM. Investigation of the effect of oral metformin on dipeptidylpeptidase-4 (DPP-4) activity in type 2 diabetes. Diabet Med. 2009;26(6):649-654.
59. Nauck MA. Unraveling the science of incretin biology. Am J Med. 2009; 122(6)(suppl):S3-S10.
60. Horton ES. Can newer therapies delay the progression of type 2 diabetes mellitus? Endocr Pract. 2008;14(5):625-638.
61. DeFronzo RA, Banerji M, Bray GA, et al. Actos Now for the prevention of diabetes (ACT NOW) study. BMC Endocr Disord. 2009;9:17.
62. Mari A, Degn K, Brock B, Rungby J, Ferrannini E, Schmitz O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on β-cell function in normal living conditions. Diabetes Care. 2007;30(8):2032-2033. (Pubitemid 47219415)